Filter Lifespan in Continuous Renal Replacement Therapy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Muenster

About this trial

The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.

Eligibility criteria

Qualifiers

Adult patients (age ≥18 years)

Critically ill patients with dialysis-dependent AKI

Continuous renal replacement therapy (CRRT)

Written informed consent

Disqualifiers

Chronic kidney disease with estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2

Chronic dialysis dependency

Kidney transplant

(Glomerulo-)nephritis, interstitial nephritis, vasculitis

Trial design

Treatments tested in this trial

  • Critically ill patients with continuous renal replacement therapy

Treatment groups

No treatment groups listed

Sponsors and collaborators

University Hospital Muenster

Lead sponsor

Baxter Healthcare Corporation

Collaborator